Peter Bo Poulsen
Overview
Explore the profile of Peter Bo Poulsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudolfsen J, Gluud L, Gronbaek H, Jensen M, Vyberg M, Olsen J, et al.
Ann Hepatol
. 2024 Jan;
29(3):101285.
PMID: 38272183
Introduction And Objectives: Studies on the societal burden of patients with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD) are sparse. This study examined this question, comparing NAFLD with matched reference groups....
2.
Rudolfsen J, Vissing J, Werlauff U, Olesen C, Illum N, Olsen J, et al.
J Neuromuscul Dis
. 2024 Jan;
11(2):443-457.
PMID: 38217608
Background: Duchenne Muscular Dystrophy (DMD) is a progressive genetic disease with a prevalence of 1 per 3,600-6,000 male births. Individuals with DMD are typically diagnosed at age 4-7 years; median...
3.
Frolunde A, Gren S, Frostrup A, Bo Poulsen P, Vastrup A, Vestergaard C
JMIR Dermatol
. 2023 Oct;
6:e45226.
PMID: 37796547
No abstract available.
4.
Johnsen S, Jensen M, Munster A, Frost L, Harboe L, Bo Poulsen P, et al.
Thromb Haemost
. 2023 Apr;
123(10):978-988.
PMID: 37054981
Objectives: To investigate geographical variation in initiation and extended treatment with anticoagulants and clinical outcomes among patients hospitalized with first-time venous thromboembolism (VTE) in Denmark between 2007 and 2018. Methods: ...
5.
Garly R, Berg T, Jensen M, Knoop A, Volmer L, Glavicic V, et al.
Acta Oncol
. 2023 Apr;
62(3):290-297.
PMID: 37010239
Background: The recommended first-line treatment for advanced, ER+/HER2 negative breast cancer is a CDK 4/6 inhibitor in combination with an endocrine backbone. This study investigated the use of palbociclib, as...
6.
Khan H, Rudolfsen J, Olsen J, Borgquist S, Bo Poulsen P
Cancer Manag Res
. 2023 Jan;
15:43-53.
PMID: 36660236
Background: Historically, Denmark has had poor survival for cancer patients relative to other western countries with comparable health-care systems. In this study, we examine the long-term cancer impact of a...
7.
Olsen J, Schnack H, Skovdal M, Vietri J, Mikkelsen M, Bo Poulsen P
J Med Econ
. 2022 Nov;
25(1):1240-1254.
PMID: 36426797
Background: A new 20-valent pneumococcal conjugate vaccine (PCV20) provides protection against 20 pneumococcal serotypes. The vaccine has the potential to decrease the impact of pneumococcal diseases in society and to...
8.
Bo Poulsen P, Hemmingsen U, Melgaard T, Elleby H, Wedell-Wedellsborg D, Dybro L, et al.
Scand Cardiovasc J
. 2022 Jul;
56(1):243-246.
PMID: 35801631
Current evidence base for atrial fibrillation (AF) screening is insufficient. An important finding in the STROKESTOP study was that non-participants had significantly worse outcomes. In a group of potentially non-participants...
9.
Jakobsen M, Kolodziejczyk C, Jensen M, Bo Poulsen P, Khan H, Kumler T, et al.
BMC Cancer
. 2021 Sep;
21(1):1040.
PMID: 34537007
Background: There is increasing concern about cardiovascular disease (CVD) after breast cancer (BC). The aim of this study was to estimate the prevalence of different types of CVD in women...
10.
Kolodziejczyk C, Jakobsen M, Jensen M, Bo Poulsen P, Khan H, Kumler T, et al.
Acta Oncol
. 2021 Aug;
60(10):1257-1263.
PMID: 34339355
Background: Only few existing studies have investigated the mortality from cardiovascular disease (CVD) in women with breast cancer (BC). The aim of this study was to investigate CVD mortality in...